Treatment of chronic he1patitis C genotype 1 with peginterferon-alpha2a (40 kDa) plus ribavirin under routine clinical practice in Spain: early prediction of sustained virological response rate.

Abstract

BACKGROUND:

Sustained virological response rates of up to 52% have been obtained with peginterferon alpha2a (40 kDa) plus ribavirin in patients suffering from chronic hepatitis C genotype 1 in randomized-controlled trials.

AIM:

To assess early virological response and its clinical utility in predicting an sustained virological response in patients suffering from chronic hepatitis C genotype 1 in routine clinical practice in Spain.

METHODS:

Treatment-naïve patients received pegylated interferon alpha2a (40 kDa) 180 microg/week plus ribavirin 1000/1200 mg/day for 48 weeks, and were followed for a further 24 weeks. Overall, 475 patients received at least one dose of medication and were included in the efficacy population.

RESULTS:

The overall sustained virological response rate was 48%. Of those with week 12 virological data, 83% had an early virological response. The negative predictive value of an early virological response was 93%.

CONCLUSION:

If sustained virological response is the goal, a treatment-decision based on a 12-week evaluation during routine clinical practice is feasible.

• Authors: M Diago, A Olveira, R Solá, M Romero-Gómez, R Moreno-Otero, R Pérez, J Salmerón, J Enríquez, R Planas, J C Gavilán, J Del Olmo, R Uribarrena, C Sillero, A Benítez, S Sánchez-Galdón, B Dalmau, L Eraña, M Montoro, J Portu, J M Garijo, R Barniol, A Domínguez, R Rota, J L Olcoz, M Antón, X Pamplona, T Casanovas, E Jiménez, M Huarte, F Díaz, J Sánchez-Ruano, M Orive, M Muñoz-Sánchez, M Roset
• Journal: Alimentary pharmacology & therapeutics (Aliment Pharmacol Ther) Vol. 25 Issue 8 Pg. 899-906 (Apr 15 2007) ISSN: 0269-2813 [Print] England
• PMID: 17402993 (Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Chemical References

• Antiviral Agents
• Interferon alpha-2
• Interferon-alpha
• Recombinant Proteins
• Polyethylene Glycols
• Ribavirin
• peginterferon alfa-2a

Topics

• Adult
• Antiviral Agents (pharmacokinetics, therapeutic use)
• Drug Therapy, Combination
• Female
• Hepatitis C, Chronic (drug therapy, virology)
• Humans
• Interferon alpha-2
• Interferon-alpha (pharmacokinetics, therapeutic use)
• Male
• Middle Aged
• Polyethylene Glycols (pharmacokinetics, therapeutic use)
• Recombinant Proteins
• Ribavirin (pharmacokinetics, therapeutic use)
• Treatment Outcome